RecruitingNCT05264051
MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease
Sponsor
University of Chicago
Enrollment
1,200 participants
Start Date
Apr 18, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of the study is to study the muscle assessment score (MAsS, utilizing MRI, as an objective measure of frailty and muscle composition to serve as a predictor of morbidity and mortality in patients with liver disease.
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- Patients who are already scheduled for an MRI for routine clinical purposes will be evaluated
Exclusion Criteria1
- <18 yrs. of age
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05264051
Related Trials
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment
NCT075594744 locations
Primary Sclerosing Cholangitis in Children
NCT0418113812 locations
Comparison of Inflammatory Profiles and Regenerative Potential in Alcoholic Liver Disease
NCT037738871 location
China Metastatic Liver Cancer Clinical Registry Cohort Database
NCT076025043 locations
The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine
NCT071506241 location